Results

1–8 of 8 results for RHINE

Time to Retinal Fluid Control With Faricimab vs Aflibercept in Patients With DME in the Phase 3 YOSEMITE/RHINE Trials
Aleksandra V. Rachitskaya, MD, FASRS
Annual Meeting Talks
2023
Impact of Faricimab vs Aflibercept on Epiretinal Membrane Formation Over 2 Years in Eyes With DME in the YOSEMITE/RHINE Phase 3 Trials
Glenn J. Jaffe, MD
Annual Meeting Talks
2023
Expert Panel: Faricimab and Aflibercept 8 mg in Diabetic Retinopathy
Judy E. Kim, MD, FASRS
Chirag D. Jhaveri, MD, FASRS
Michael S. Ip, MD
Arshad M. Khanani, MD, MA, FASRS
Jordana G Fein, MD, MS
Dennis M. Marcus, MD
Diana V Do, MD, FASRS
Annual Meeting Talks
2024
Personalized Treatment Interval Dosing Dynamics Over 2 Years in the Phase 3 YOSEMITE and RHINE Trials of Faricimab in Diabetic Macular Edema
John W. Kitchens, MD
Annual Meeting Talks
2022
Efficacy, Durability, and Safety of Faricimab in Diabetic Macular Edema: 2-Year Results of the Phase 3 YOSEMITE and RHINE Trials
David A. Eichenbaum, MD, FASRS
Annual Meeting Talks
2022
Efficacy, Safety, and Durability of Faricimab in Diabetic Macular Edema (DME): One-Year Results From the Phase 3 YOSEMITE and RHINE Trials
Caroline Baumal, MD, FASRS
Annual Meeting Talks
2021
Efficacy, Durability, and Safety of Faricimab in DME: 2-Year Results From the Phase 3 YOSEMITE and RHINE Trials
Jennifer I. Lim, MD, FARVO, FASRS
Updates from the Field
2022
Efficacy, Safety, and Durability of Faricimab in Diabetic Macular Edema (DME): One-Year Results From the Phase 3 YOSEMITE and RHINE Trials
Caroline Baumal, MD, FASRS
Updates from the Field
2021